Pharmacokinetic Study of Livalo� Fixed Combination Drug in Healthy Subjects
Information source: JW Pharmaceutical
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hyperlipidemia; Hypertension
Intervention: Pitavastatin, Valsartan (Drug); Livalo® fixed combination drug (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: JW Pharmaceutical Official(s) and/or principal investigator(s):
Kyun Seop Bae, MD, Principal Investigator, Affiliation: Asan Medical Center
Summary
The purpose of this study is to compare pharmacokinetics between Pitavastatin and Valsartan
co-administration and Livalo fixed combination drug in healthy male subjects.
Clinical Details
Official title: A Single Dose, Sequence-randomized, Open-label, 2x2 Crossover Study to Compare Pharmacokinetics Between Pitavastatin and Valsartan Co-administration and Livalo® Fixed Combination Drug in Healthy Male Subjects
Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label
Primary outcome: Cmax of study drugs after single oral administrationAUClast of study drugs after single oral administration
Secondary outcome: AUCinf, Tmax and t1/2β of study drugs after single oral administration
Eligibility
Minimum age: 20 Years.
Maximum age: 55 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Healthy male volunteers
- Age 20-55 years at the time of Screening
- BMI 19-26 kg/m2 at the time of Screening
Exclusion Criteria:
- Received other investigational drug within 90 days prior to the first dose of study
drug
Locations and Contacts
Asan Medical Center, Seoul, Korea, Republic of
Additional Information
Starting date: August 2011
Last updated: January 1, 2013
|
